Inspra
(eplerenone)ApprovedSmall molecule
Eplerenone is used to treat high blood pressure and to improve survival in patients who have had a heart attack. It helps the body retain less salt and water, which reduces strain on the heart and blood vessels.[2] Inspra is currently approved and in use across 33 indications[4].[1]
Inspra is one of 573 small molecule programs targeting Central Serous Retinopathy. It is currently in Approved.
33
Indications
95
Total Trials
13
Active Trials
572
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 33 indications
Competition
Competitive Landscape
206 competitors in Heart Failure
#DrugCompanyPhaseTrials
1Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Brethine
SanofiPreclinical
Medrol
PfizerPreclinical
Amidate
PfizerPreclinical
Zemplar
AbbViePreclinical
Adriamycin
PfizerPreclinical
Savaysa
Daiichi SankyoPreclinical
Xifaxan
SSalix
Preclinical
Oraverse
LLife Extension Foundation Inc.
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hypertension10 trials
Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension
Recruiting·—·Phase 4·NCT05593055·75 enrolled
Show 7 more trials
A Study to Evaluate the Efficacy and Safety of Eplerenone in the Treatment of Hypertension in Children.
Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 3·NCT00147589·320 enrolled
Retinopathy5 trials
Heart Failure5 trials
The Purpose of This Study is to Determine if Eplerenone is Effective in Treatment of Mild to Moderate Heart Failure
Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 4·NCT00082589·250 enrolled
Show 2 more trials
Clinical Study Of Eplerenone In Japanese Patients With Chronic Heart Failure
Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 3·NCT01115855·221 enrolled
Chronic Kidney Disease4 trials
Essential Hypertension4 trials
Aldosterone Blockade to Prevent Myocardial Remodeling In Patients With Controlled Essential Hypertension
Terminated·—·N/A·NCT00980031·20 enrolled
51 more indications
Tics4 trials
Primary Aldosteronism3 trials
Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study
Recruiting·—·Phase 4·NCT05030545·40 enrolled
Diastolic Heart Failure3 trials
Type 2 Diabetes2 trials
Cardiomyopathy2 trials
Preeclampsia2 trials
MR and Inflammation After Preeclampsia
Active, not recruiting·—·Phase 1·NCT07345845·40 enrolled
Vascular Effects of High-Salt After Preeclampsia
Recruiting·—·Phase 1·NCT06749418·40 enrolled
Blood Pressure2 trials
Metabolic Syndrome2 trials
Atrial Fibrillation2 trials
Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patient With Structural Heart Disease
Not yet recruiting·—·Phase 4·NCT06168994·100 enrolled
Duchenne Muscular Dystrophy2 trials
Myocardial Ischemia1 trial
Efficacy and Safety1 trial
ALD1 trial
The Role of Minerelocorticoid Receptor on Modulating Aldosterone Production
Completed·—·Phase 1·NCT02871648·23 enrolled
Breast Cancer1 trial
Systolic Heart Failure1 trial
A Registry-based Cluster Randomized Trial to Compare the Effect of Spironolactone vs. Eplerenone on Clinical Outcomes in Patients With Symptomatic Systolic Heart Failure
Enrolling by invitation·—·Phase 4·NCT03984591·7,200 enrolled
Hypertrophy1 trial
Ischemia Reperfusion Injury1 trial
Renal Transplant1 trial
Eplerenone in Patients Undergoing REnal Transplant (EPURE TRANSPLANT)
Active, not recruiting·—·Phase 3·NCT02490904·132 enrolled
Primary Hyperparathyroidism1 trial
Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism
Completed·—·Phase 2/3·NCT02525796·69 enrolled
Myocardial Infarction1 trial
Impact Of Eplerenone On Cardiovascular Outcomes In Patients Post Myocardial Infarction
Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 4·NCT01176968·1,012 enrolled
Type 2 Diabetes Mellitus1 trial
Inflammatory Response1 trial
Effect of Eplerenone on Postprandial Inflammatory Response in Healthy Adults
Completed·—·N/A·NCT01786551·16 enrolled
Effectiveness1 trial
Cardiovascular Disease1 trial
Congenital Heart Disease1 trial
Diabetes Mellitus1 trial
Aldosterone and Vascular Disease in Diabetes Mellitus
Completed·—·N/A·NCT00214825·46 enrolled
Left Ventricular Hypertrophy1 trial
Treatment1 trial
Biomarkers1 trial
Single Dose1 trial
Glucose intolerance1 trial
LSD1 trial
MR Antagonist and LSD1
Active, not recruiting·—·Phase 4·NCT04840342·300 enrolled
Cirrhosis1 trial
Hypoglycemia1 trial
Hypoglycemia and the Mineralocorticoid Receptor
Completed·—·N/A·NCT01394627·21 enrolled
Diabetes1 trial
Detection of Diffuse Scar in Patients With Diabetes
Withdrawn·—·Phase 4·NCT01794091
Kidney Disease1 trial
Kidney1 trial
Intraocular Pressure1 trial
Regulatory
FDA Approval Timeline[5]
Sep 27, 2002
INSPRA
NDA NDA021437
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Inspra drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for eplerenone. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details